A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries

Journal of Internal Medicine

Volumn 256, Issue 5, 2004, Pages 388-397

  Hausleiter, Jörg ^a   Kastrati, A ^a   Mehilli, J ^a   Schuhlen H ^b   Pache, J ^a   Dotzer, F ^c   Glatthor, C ^c   Siebert, S ^a   Dirschinger, J ^b   Schomig A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Med Klin I Klin Garmisch P   (Germany)

Author keywords

Balloon angioplasty; Coronary artery disease; Glycoprotein IIb IIIa antagonists; Platelets; Restenosis; Stents

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HEPARIN; PHOSPHORYLCHOLINE; PLACEBO;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; FEMALE; HUMAN; INTRACORONARY INFUSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CORONARY RESTENOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; PHOSPHORYLCHOLINE; PLATELET AGGREGATION INHIBITORS; STENTS; TREATMENT OUTCOME;

EID: 7244231499     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2004.01398.x     Document Type: Article

References (30)

1. Park SW, Lee CW, Hong MK et al. Randomized comparison of coronary stenting with optimal balloon angioplasty for treatment of lesions in small coronary arteries. Eur Heart J 2000; 21: 1785-9.
2. Kastrati A, Schömig A, Dirschinger J et al. A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. Circulation 2000; 102: 2593-8.
3. Koning R, Eltchaninoff H, Commeau P et al. Stent placement compared with balloon angioplasty for small coronary arteries: in-hospital and 6-month clinical and angiographic results. Circulation 2001; 104: 1604-8.
4. Doucet S, Schalij MJ, Vrolix MC et al. Stent placement to prevent restenosis after angioplasty in small coronary arteries. Circulation 2001; 104: 2029-33.
5. Garcia E, Gomez-Recio M, Moreno R et al. Stent reduces restenosis in small vessels. Results of the RAP study. J Am Coll Cardiol 2001; 37: 17A.
6. Moer R, Myreng Y, Molstad P et al. Stenting in small coronary arteries (SISCA) trial. A randomized comparison between balloon angioplasty and the heparin-coated beStent. J Am Coll Cardiol 2001; 38: 1598-603.
7. Haude M, Konorza TF, Kalnins U et al. Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients. Circulation 2003; 107: 1265-70.
8. Chen C, Ofenloch JC, Yianni YP, Hanson SR, Lumsden AB. Phosphorylcholine coating of ePTFE reduces platelet deposition and neointimal hyperplasia in arteriovenous grafts. J Surg Res 1998; 77: 119-25.
9. Bauters C, LaBlanche JM, McFadden EP, Hamon M, Bertrand ME. Relation of coronary angioscopic findings at coronary angioplasty to angiographic restenosis. Circulation 1995; 92: 2473-9.
10. Wilensky RL, March KL, Gradus-Pizlo I, Sandusky G, Fineberg N, Hathaway DR. Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit. Circulation 1996; 92: 2995-3005.
11. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956-61.
12. Lincoff AM, Califf RM, Moliterno DJ et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999; 341: 319-27.
13. The ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation 1999; 100: 799-806.
14. Ellis SG, Vandormael MG, Cowley MJ et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Circulation 1990; 82: 1193-202.
15. Hausleiter J, Jost S, Nolte CW et al. Comparative in-vitro validation of eight first- and second-generation quantitative coronary angiography systems. Coron Artery Dis 1997; 8: 83-90.
16. Topol EJ, Mark DB, Lincoff AM et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999; 354: 2019-24.
17. Serruys PW, Buller C, Bonnier JJ et al. Quantitative angiographic results of the phosphorylcholine coated bio-divYsio stent in the SOPHOS study. Eur Heart J 1999; 20: 272.
18. Kastrati A, Schühlen H, Schömig A. Stenting for small coronary vessels: a contestable winner. J Am Coll Cardiol 2001; 38: 1604-7.
19. Hausleiter J, Kastrati A, Mehilli J et al. Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. J Am Coll Cardiol 2002; 40: 882.
20. Briguori C, Sarais C, Pagnotta P et al. In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol 2002; 40: 403-9.
21. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-23.
22. Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-31.
23. Topol EJ, Lincoff AM, Kereiakes DJ et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002; 113: 1-6.
24. Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro. chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 1998; 98: 1085-91.
25. Blindt R, Bosserhoff AK, Zeiffer U, Krott N, Hanrath P, vom Dahl J. Abciximab inhibits the migration and invasion potential of human coronary artery smooth muscle cells. J Mol Cell Cardiol 2000; 32: 2195-206.
26. Steinhubl SR, Ellis SG, Wolski K, Lincoff AM, Topol EJ. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation 2001; 103: 1403-9.
27. Müller I, Seyfarth M, Rudiger S et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-3.
28. Kastrati A, Mehilli J, Schühlen H A double-blind placebo-controlled, randomized trial evaluating the glycoprotein IIb/IIIa inhibitor abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. N Engl J Med 2004; 350: 232-8.
29. Srivatsa SS, Fitzpatrick LA, Tsao PW et al. Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation. Cardiovasc Res 1997; 36: 408-28.
30. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87-92.